Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	protein phosphatase activator activity	PPP2R5B PPP2R5C PPP2R5D	4.60e-06	17	39	3	GO:0072542
GeneOntologyMolecularFunction	phosphatase activator activity	PPP2R5B PPP2R5C PPP2R5D	7.67e-06	20	39	3	GO:0019211
GeneOntologyMolecularFunction	testosterone 6-beta-hydroxylase activity	CYP3A7 CYP3A5	3.70e-05	5	39	2	GO:0050649
GeneOntologyMolecularFunction	steroid hydroxylase activity	CYP3A7 CYP3A5 CYP11A1	3.95e-05	34	39	3	GO:0008395
GeneOntologyMolecularFunction	estrogen 2-hydroxylase activity	CYP3A7 CYP3A5	1.03e-04	8	39	2	GO:0101021
GeneOntologyMolecularFunction	estrogen 16-alpha-hydroxylase activity	CYP3A7 CYP3A5	2.02e-04	11	39	2	GO:0101020
GeneOntologyMolecularFunction	retinoic acid 4-hydroxylase activity	CYP3A7 CYP3A5	3.33e-04	14	39	2	GO:0008401
GeneOntologyMolecularFunction	floppase activity	ABCA2 ABCA7	4.38e-04	16	39	2	GO:0140328
GeneOntologyMolecularFunction	lipid transporter activity	ABCA2 ABCA7 CFHR4 ATG2B	5.66e-04	196	39	4	GO:0005319
GeneOntologyMolecularFunction	protein phosphatase regulator activity	PPP2R5B PPP2R5C PPP2R5D	9.77e-04	100	39	3	GO:0019888
GeneOntologyMolecularFunction	ATPase-coupled intramembrane lipid transporter activity	ABCA2 ABCA7	1.36e-03	28	39	2	GO:0140326
GeneOntologyMolecularFunction	phosphatase regulator activity	PPP2R5B PPP2R5C PPP2R5D	1.39e-03	113	39	3	GO:0019208
GeneOntologyMolecularFunction	monooxygenase activity	CYP3A7 CYP3A5 CYP11A1	1.46e-03	115	39	3	GO:0004497
GeneOntologyMolecularFunction	aromatase activity	CYP3A7 CYP3A5	2.12e-03	35	39	2	GO:0070330
GeneOntologyMolecularFunction	oxygen binding	CYP3A7 CYP3A5	2.37e-03	37	39	2	GO:0019825
GeneOntologyMolecularFunction	heme binding	CYP3A7 CYP3A5 CYP11A1	3.35e-03	154	39	3	GO:0020037
GeneOntologyMolecularFunction	sulfur compound binding	ADAMTS5 TNXB RYR2 CFHR4	3.54e-03	323	39	4	GO:1901681
GeneOntologyMolecularFunction	phosphatidylinositol-3-phosphate binding	ZFYVE26 ATG2B	3.96e-03	48	39	2	GO:0032266
GeneOntologyMolecularFunction	tetrapyrrole binding	CYP3A7 CYP3A5 CYP11A1	4.00e-03	164	39	3	GO:0046906
GeneOntologyMolecularFunction	ABC-type transporter activity	ABCA2 ABCA7	4.13e-03	49	39	2	GO:0140359
GeneOntologyMolecularFunction	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	CYP3A7 CYP3A5	4.13e-03	49	39	2	GO:0016712
GeneOntologyMolecularFunction	iron ion binding	CYP3A7 CYP3A5 CYP11A1	4.14e-03	166	39	3	GO:0005506
GeneOntologyMolecularFunction	intramembrane lipid transporter activity	ABCA2 ABCA7	4.46e-03	51	39	2	GO:0140303
GeneOntologyMolecularFunction	heparin binding	ADAMTS5 TNXB CFHR4	6.20e-03	192	39	3	GO:0008201
GeneOntologyMolecularFunction	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen	CYP3A7 CYP3A5 CYP11A1	6.38e-03	194	39	3	GO:0016705
GeneOntologyMolecularFunction	phosphatidylinositol phosphate binding	ZFYVE26 FRMPD4 ATG2B	6.84e-03	199	39	3	GO:1901981
GeneOntologyMolecularFunction	extracellular matrix binding	ADAMTS5 TNXB	8.95e-03	73	39	2	GO:0050840
GeneOntologyCellularComponent	protein phosphatase type 2A complex	PPP2R5B PPP2R5C PPP2R5D	4.44e-06	18	38	3	GO:0000159
GeneOntologyCellularComponent	protein serine/threonine phosphatase complex	PPP2R5B PPP2R5C PPP2R5D	1.36e-04	55	38	3	GO:0008287
GeneOntologyCellularComponent	phosphatase complex	PPP2R5B PPP2R5C PPP2R5D	1.36e-04	55	38	3	GO:1903293
MousePheno	abnormal motor coordination/balance	ZFYVE26 ABCA2 FUCA1 PPP2R5C PPP2R5D CERS1 CWH43 ANKFN1 NLK GNPTAB	1.14e-05	873	31	10	MP:0001516
MousePheno	brain atrophy	ZFYVE26 CERS1 GNPTAB	2.20e-05	25	31	3	MP:0012506
MousePheno	Purkinje cell degeneration	ZFYVE26 FUCA1 CERS1 GNPTAB	2.92e-05	81	31	4	MP:0000876
MousePheno	gliosis	ZFYVE26 FUCA1 CERS1 OGG1 GNPTAB	3.39e-05	171	31	5	MP:0002183
MousePheno	astrocytosis	ZFYVE26 FUCA1 CERS1 GNPTAB	7.51e-05	103	31	4	MP:0003354
MousePheno	increased astrocyte number	ZFYVE26 FUCA1 CERS1 GNPTAB	8.71e-05	107	31	4	MP:0012065
MousePheno	abnormal astrocyte number	ZFYVE26 FUCA1 CERS1 GNPTAB	1.04e-04	112	31	4	MP:0012064
MousePheno	abnormal locomotor coordination	ZFYVE26 FUCA1 PPP2R5C CERS1 CWH43 ANKFN1 NLK GNPTAB	1.38e-04	726	31	8	MP:0003312
MousePheno	abnormal urinary bladder morphology	ZFYVE26 FUCA1 RET AASS GNPTAB	1.93e-04	247	31	5	MP:0000538
MousePheno	abnormal adrenal chromaffin cell morphology	RET CYP11A1	2.12e-04	10	31	2	MP:0008504
MousePheno	ataxia	ZFYVE26 FUCA1 CERS1 NLK GNPTAB	2.72e-04	266	31	5	MP:0001393
MousePheno	abnormal CNS glial cell morphology	ZFYVE26 FUCA1 CERS1 OGG1 GNPTAB	3.02e-04	272	31	5	MP:0000952
MousePheno	abnormal bulbourethral gland morphology	CYP11A1 GNPTAB	3.10e-04	12	31	2	MP:0001169
MousePheno	abnormal lysosome morphology	ZFYVE26 FUCA1 GNPTAB	3.26e-04	61	31	3	MP:0005058
MousePheno	abnormal astrocyte morphology	ZFYVE26 FUCA1 CERS1 GNPTAB	3.62e-04	155	31	4	MP:0002182
MousePheno	abnormal vacuole morphology	ZFYVE26 FUCA1 GNPTAB	4.11e-04	66	31	3	MP:0020851
MousePheno	impaired coordination	ZFYVE26 FUCA1 PPP2R5D CWH43 NLK GNPTAB	5.51e-04	478	31	6	MP:0001405
MousePheno	abnormal ear physiology	KLHDC7B ZFYVE26 FUCA1 ANKFN1 NLK TMEM145 ATG2B	6.11e-04	684	31	7	MP:0003878
MousePheno	abnormal neuroendocrine cell morphology	RET CYP11A1	6.34e-04	17	31	2	MP:0010913
MousePheno	cerebellum atrophy	CERS1 GNPTAB	6.34e-04	17	31	2	MP:0014185
MousePheno	hindbrain atrophy	CERS1 GNPTAB	6.34e-04	17	31	2	MP:0014184
MousePheno	axonal spheroids	FUCA1 GNPTAB	6.34e-04	17	31	2	MP:0010047
MousePheno	abnormal adrenal medulla morphology	RET CYP11A1	7.12e-04	18	31	2	MP:0008289
MousePheno	abnormal glial cell morphology	ZFYVE26 FUCA1 CERS1 OGG1 GNPTAB	8.91e-04	345	31	5	MP:0003634
MousePheno	abnormal sensory capabilities/reflexes/nociception	KLHDC7B ABCA2 PPP2R5C ADAMTS5 PPP2R5D FRMPD4 NLK RYR2 GNPTAB TMEM145	9.74e-04	1486	31	10	MP:0002067
MousePheno	lipofuscinosis	FUCA1 CERS1	9.74e-04	21	31	2	MP:0008842
MousePheno	abnormal vas deferens morphology	RET CYP11A1	9.74e-04	21	31	2	MP:0002769
MousePheno	tremors	ZFYVE26 ABCA2 FUCA1 CERS1 ANKFN1	9.88e-04	353	31	5	MP:0000745
MousePheno	abnormal Purkinje cell morphology	ZFYVE26 FUCA1 CERS1 GNPTAB	1.02e-03	204	31	4	MP:0000877
MousePheno	axon degeneration	ZFYVE26 FUCA1 GNPTAB	1.05e-03	91	31	3	MP:0005405
MousePheno	abnormal cognition	GPR6 ZFYVE26 ABCA2 FUCA1 PPP2R5C CERS1 ANKFN1 GNPTAB ATG2B	1.14e-03	1246	31	9	MP:0014114
MousePheno	abnormal cerebellar Purkinje cell layer	ZFYVE26 FUCA1 CERS1 GNPTAB	1.35e-03	220	31	4	MP:0000875
Domain	PP2A_B56	PPP2R5B PPP2R5C PPP2R5D	7.14e-08	5	37	3	IPR002554
Domain	B56	PPP2R5B PPP2R5C PPP2R5D	7.14e-08	5	37	3	PF01603
Domain	Cyt_P450_E_grp-II	CYP3A7 CYP3A5	3.80e-05	5	37	2	IPR002402
Domain	Cyt_P450_E_CYP3A	CYP3A7 CYP3A5	5.70e-05	6	37	2	IPR008072
Domain	Cyt_P450_E_grp-I	CYP3A7 CYP3A5 CYP11A1	9.59e-05	45	37	3	IPR002401
Domain	Cyt_P450_CS	CYP3A7 CYP3A5 CYP11A1	1.57e-04	53	37	3	IPR017972
Domain	CYTOCHROME_P450	CYP3A7 CYP3A5 CYP11A1	1.95e-04	57	37	3	PS00086
Domain	p450	CYP3A7 CYP3A5 CYP11A1	2.05e-04	58	37	3	PF00067
Domain	Cyt_P450	CYP3A7 CYP3A5 CYP11A1	2.27e-04	60	37	3	IPR001128
Domain	ABC_A	ABCA2 ABCA7	2.49e-04	12	37	2	IPR026082
Domain	ABC_transporter_CS	ABCA2 ABCA7	3.13e-03	42	37	2	IPR017871
Domain	ABC_TRANSPORTER_2	ABCA2 ABCA7	4.07e-03	48	37	2	PS50893
Domain	ABC_tran	ABCA2 ABCA7	4.07e-03	48	37	2	PF00005
Domain	ABC_TRANSPORTER_1	ABCA2 ABCA7	4.24e-03	49	37	2	PS00211
Domain	ARM-type_fold	PPP2R5B PPP2R5C PPP2R5D USP9Y	4.39e-03	339	37	4	IPR016024
Domain	ABC_transporter-like	ABCA2 ABCA7	4.41e-03	50	37	2	IPR003439
Domain	-	CYP3A5 CYP11A1	5.89e-03	58	37	2	1.10.630.10
Pathway	REACTOME_SIGNALING_BY_CTNNB1_PHOSPHO_SITE_MUTANTS	PPP2R5B PPP2R5C PPP2R5D	3.14e-06	15	28	3	M27407
Pathway	KEGG_MEDICUS_REFERENCE_COHESIN_DISSOCIATION_IN_PROPHASE	PPP2R5B PPP2R5C PPP2R5D	3.86e-06	16	28	3	M47870
Pathway	REACTOME_PLATELET_SENSITIZATION_BY_LDL	PPP2R5B PPP2R5C PPP2R5D	4.68e-06	17	28	3	MM15096
Pathway	REACTOME_BETA_CATENIN_PHOSPHORYLATION_CASCADE	PPP2R5B PPP2R5C PPP2R5D	4.68e-06	17	28	3	M27083
Pathway	REACTOME_PLATELET_SENSITIZATION_BY_LDL	PPP2R5B PPP2R5C PPP2R5D	4.68e-06	17	28	3	M919
Pathway	REACTOME_BETA_CATENIN_PHOSPHORYLATION_CASCADE	PPP2R5B PPP2R5C PPP2R5D	5.61e-06	18	28	3	MM14759
Pathway	KEGG_MEDICUS_REFERENCE_PP2A_AKT_SIGNALING_PATHWAY	PPP2R5B PPP2R5C PPP2R5D	6.66e-06	19	28	3	M47525
Pathway	KEGG_MEDICUS_REFERENCE_CONDENSIN_LOADING	PPP2R5B PPP2R5C PPP2R5D	7.82e-06	20	28	3	M47876
Pathway	REACTOME_CTLA4_INHIBITORY_SIGNALING	PPP2R5B PPP2R5C PPP2R5D	9.11e-06	21	28	3	M5876
Pathway	REACTOME_CTLA4_INHIBITORY_SIGNALING	PPP2R5B PPP2R5C PPP2R5D	9.11e-06	21	28	3	MM14996
Pathway	KEGG_MEDICUS_REFERENCE_CD80_CD86_CTLA4_PP2A_SIGNALING_PATHWAY	PPP2R5B PPP2R5C PPP2R5D	1.05e-05	22	28	3	M47919
Pathway	REACTOME_DISASSEMBLY_OF_THE_DESTRUCTION_COMPLEX_AND_RECRUITMENT_OF_AXIN_TO_THE_MEMBRANE	PPP2R5B PPP2R5C PPP2R5D	3.04e-05	31	28	3	M27400
Pathway	REACTOME_DISASSEMBLY_OF_THE_DESTRUCTION_COMPLEX_AND_RECRUITMENT_OF_AXIN_TO_THE_MEMBRANE	PPP2R5B PPP2R5C PPP2R5D	3.04e-05	31	28	3	MM15154
Pathway	REACTOME_SIGNALING_BY_WNT_IN_CANCER	PPP2R5B PPP2R5C PPP2R5D	4.03e-05	34	28	3	M27405
Pathway	REACTOME_RAF_ACTIVATION	PPP2R5B PPP2R5C PPP2R5D	4.03e-05	34	28	3	M27556
Pathway	WP_GLYCOGEN_METABOLISM	PPP2R5B PPP2R5C PPP2R5D	4.03e-05	34	28	3	MM15985
Pathway	WP_COHESIN_COMPLEX_CORNELIA_DE_LANGE_SYNDROME	PPP2R5B PPP2R5C PPP2R5D	4.03e-05	34	28	3	M42555
Pathway	WP_IL6_SIGNALING_PATHWAY	PPP2R5B PPP2R5C PPP2R5D NLK	4.28e-05	100	28	4	MM15826
Pathway	REACTOME_RAF_ACTIVATION	PPP2R5B PPP2R5C PPP2R5D	4.40e-05	35	28	3	MM15271
Pathway	WP_GLYCOGEN_SYNTHESIS_AND_DEGRADATION	PPP2R5B PPP2R5C PPP2R5D	6.60e-05	40	28	3	M39595
Pathway	REACTOME_NEGATIVE_REGULATION_OF_MAPK_PATHWAY	PPP2R5B PPP2R5C PPP2R5D	7.65e-05	42	28	3	MM15274
Pathway	REACTOME_NEGATIVE_REGULATION_OF_MAPK_PATHWAY	PPP2R5B PPP2R5C PPP2R5D	8.21e-05	43	28	3	M27560
Pathway	KEGG_STEROID_HORMONE_BIOSYNTHESIS	CYP3A7 CYP3A5 CYP11A1	1.72e-04	55	28	3	M14933
Pathway	KEGG_WNT_SIGNALING_PATHWAY	PPP2R5B PPP2R5C PPP2R5D NLK	2.12e-04	151	28	4	M19428
Pathway	WP_OXIDATION_BY_CYTOCHROME_P450	CYP3A7 CYP3A5 CYP11A1	2.45e-04	62	28	3	M39653
Pathway	REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE	CYP3A7 CYP3A5 CYP11A1	2.70e-04	64	28	3	M5650
Pathway	REACTOME_COSTIMULATION_BY_THE_CD28_FAMILY	PPP2R5B PPP2R5C PPP2R5D	2.95e-04	66	28	3	MM14990
Pathway	REACTOME_COSTIMULATION_BY_THE_CD28_FAMILY	PPP2R5B PPP2R5C PPP2R5D	4.14e-04	74	28	3	M17386
Pathway	REACTOME_PLATELET_HOMEOSTASIS	PPP2R5B PPP2R5C PPP2R5D	4.48e-04	76	28	3	MM15051
Pathway	REACTOME_DEGRADATION_OF_BETA_CATENIN_BY_THE_DESTRUCTION_COMPLEX	PPP2R5B PPP2R5C PPP2R5D	5.02e-04	79	28	3	MM14754
Pathway	REACTOME_ABC_TRANSPORTERS_IN_LIPID_HOMEOSTASIS	ABCA2 ABCA7	5.08e-04	17	28	2	MM14552
Pathway	REACTOME_ABC_TRANSPORTERS_IN_LIPID_HOMEOSTASIS	ABCA2 ABCA7	5.71e-04	18	28	2	M524
Pathway	REACTOME_DEGRADATION_OF_BETA_CATENIN_BY_THE_DESTRUCTION_COMPLEX	PPP2R5B PPP2R5C PPP2R5D	6.22e-04	85	28	3	M27079
Pathway	REACTOME_PLATELET_HOMEOSTASIS	PPP2R5B PPP2R5C PPP2R5D	6.43e-04	86	28	3	M916
Pathway	REACTOME_XENOBIOTICS	CYP3A7 CYP3A5	9.38e-04	23	28	2	M5372
Pathway	REACTOME_AMPLIFICATION_OF_SIGNAL_FROM_THE_KINETOCHORES	PPP2R5B PPP2R5C PPP2R5D	9.98e-04	100	28	3	MM14561
Pathway	WP_ESTROGEN_METABOLISM_WP5276	CYP3A7 CYP3A5	1.02e-03	24	28	2	M46445
Pathway	REACTOME_PHASE_I_FUNCTIONALIZATION_OF_COMPOUNDS	CYP3A7 CYP3A5 CYP11A1	1.12e-03	104	28	3	M738
Pathway	REACTOME_SIGNALING_BY_WNT	PPP2R5B PPP2R5C PPP2R5D NLK	1.20e-03	239	28	4	MM14756
Pathway	REACTOME_MITOTIC_SPINDLE_CHECKPOINT	PPP2R5B PPP2R5C PPP2R5D	1.35e-03	111	28	3	M27673
Pathway	KEGG_OOCYTE_MEIOSIS	PPP2R5B PPP2R5C PPP2R5D	1.42e-03	113	28	3	M16817
Pathway	REACTOME_NEGATIVE_REGULATION_OF_THE_PI3K_AKT_NETWORK	PPP2R5B PPP2R5C PPP2R5D	1.42e-03	113	28	3	MM14783
Pathway	KEGG_LINOLEIC_ACID_METABOLISM	CYP3A7 CYP3A5	1.49e-03	29	28	2	M2920
Pathway	REACTOME_MITOTIC_SPINDLE_CHECKPOINT	PPP2R5B PPP2R5C PPP2R5D	1.57e-03	117	28	3	MM15387
Pathway	REACTOME_NEGATIVE_REGULATION_OF_THE_PI3K_AKT_NETWORK	PPP2R5B PPP2R5C PPP2R5D	1.61e-03	118	28	3	M713
Pathway	KEGG_LYSOSOME	ABCA2 FUCA1 GNPTAB	1.73e-03	121	28	3	M11266
Pathway	WP_PREGNANE_X_RECEPTOR_PATHWAY	CYP3A7 CYP3A5	1.82e-03	32	28	2	M39567
Pathway	REACTOME_RESOLUTION_OF_SISTER_CHROMATID_COHESION	PPP2R5B PPP2R5C PPP2R5D	1.98e-03	127	28	3	M27181
Pathway	REACTOME_RESOLUTION_OF_SISTER_CHROMATID_COHESION	PPP2R5B PPP2R5C PPP2R5D	2.07e-03	129	28	3	MM14894
Pathway	REACTOME_RHO_GTPASES_ACTIVATE_FORMINS	PPP2R5B PPP2R5C PPP2R5D	2.62e-03	140	28	3	M27550
Pathway	REACTOME_RHO_GTPASES_ACTIVATE_FORMINS	PPP2R5B PPP2R5C PPP2R5D	2.67e-03	141	28	3	MM15266
Pathway	WP_FOCAL_ADHESION_PI3KAKTMTORSIGNALING	PPP2R5B PPP2R5C PPP2R5D TNXB	2.82e-03	302	28	4	M39719
Pathway	REACTOME_MAPK_FAMILY_SIGNALING_CASCADES	PPP2R5B PPP2R5C PPP2R5D RET	3.39e-03	318	28	4	MM15278
Pathway	KEGG_ABC_TRANSPORTERS	ABCA2 ABCA7	3.42e-03	44	28	2	M11911
Pathway	REACTOME_RHO_GTPASE_EFFECTORS	PPP2R5B PPP2R5C PPP2R5D WAS	3.59e-03	323	28	4	M27080
Pathway	REACTOME_TCF_DEPENDENT_SIGNALING_IN_RESPONSE_TO_WNT	PPP2R5B PPP2R5C PPP2R5D	3.68e-03	158	28	3	MM14791
Pathway	WP_FOCAL_ADHESION_PI3KAKTMTOR_SIGNALING_PATHWAY	PPP2R5B PPP2R5C PPP2R5D TNXB	3.71e-03	326	28	4	MM15917
Pathway	PID_PS1_PATHWAY	PPP2R5D NLK	3.73e-03	46	28	2	M70
Pathway	REACTOME_MAPK_FAMILY_SIGNALING_CASCADES	PPP2R5B PPP2R5C PPP2R5D RET	3.75e-03	327	28	4	M27565
Pathway	REACTOME_SIGNALING_BY_WNT	PPP2R5B PPP2R5C PPP2R5D NLK	3.87e-03	330	28	4	M7847
Pathway	WP_PI3KAKT_SIGNALING	PPP2R5B PPP2R5C PPP2R5D TNXB	4.26e-03	339	28	4	M39736
Pathway	KEGG_DRUG_METABOLISM_OTHER_ENZYMES	CYP3A7 CYP3A5	4.57e-03	51	28	2	M17726
Pathway	WP_METAPATHWAY_BIOTRANSFORMATION_PHASE_I_AND_II	CYP3A7 CYP3A5 CYP11A1	5.55e-03	183	28	3	M39588
Pathway	WP_SIDS_SUSCEPTIBILITY_PATHWAYS	RET RYR2	6.07e-03	59	28	2	MM15838
Pathway	REACTOME_SEPARATION_OF_SISTER_CHROMATIDS	PPP2R5B PPP2R5C PPP2R5D	6.25e-03	191	28	3	M29614
Pathway	REACTOME_SEPARATION_OF_SISTER_CHROMATIDS	PPP2R5B PPP2R5C PPP2R5D	6.43e-03	193	28	3	MM14890
Pathway	REACTOME_METABOLISM_OF_LIPIDS	PON2 CERS1 CYP3A5 CYP11A1 LPCAT3	6.86e-03	620	28	5	MM15193
Pathway	KEGG_RETINOL_METABOLISM	CYP3A7 CYP3A5	7.11e-03	64	28	2	M9488
Pathway	REACTOME_MITOTIC_PROMETAPHASE	PPP2R5B PPP2R5C PPP2R5D	7.29e-03	202	28	3	MM15362
Pathway	REACTOME_MITOTIC_PROMETAPHASE	PPP2R5B PPP2R5C PPP2R5D	7.49e-03	204	28	3	M4217
Pathway	REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE	CYP3A5 CYP11A1	7.54e-03	66	28	2	MM14839
Pubmed	Mutations in the PP2A regulatory subunit B family genes PPP2R5B, PPP2R5C and PPP2R5D cause human overgrowth.	PPP2R5B PPP2R5C PPP2R5D	1.41e-09	3	40	3	25972378
Pubmed	Assignment of human protein phosphatase 2A regulatory subunit genes b56alpha, b56beta, b56gamma, b56delta, and b56epsilon (PPP2R5A-PPP2R5E), highly expressed in muscle and brain, to chromosome regions 1q41, 11q12, 3p21, 6p21.1, and 7p11.2 --> p12.	PPP2R5B PPP2R5C PPP2R5D	1.41e-08	5	40	3	8812429
Pubmed	Genomic organisation, chromosomal localisation tissue distribution and developmental regulation of the PR61/B' regulatory subunits of protein phosphatase 2A in mice.	PPP2R5B PPP2R5C PPP2R5D	1.41e-08	5	40	3	15095873
Pubmed	The B56 family of protein phosphatase 2A (PP2A) regulatory subunits encodes differentiation-induced phosphoproteins that target PP2A to both nucleus and cytoplasm.	PPP2R5B PPP2R5C PPP2R5D	4.92e-08	7	40	3	8703017
Pubmed	Identification of a new family of protein phosphatase 2A regulatory subunits.	PPP2R5B PPP2R5C PPP2R5D	4.92e-08	7	40	3	7592815
Pubmed	Direct binding between BubR1 and B56-PP2A phosphatase complexes regulate mitotic progression.	PPP2R5B PPP2R5C PPP2R5D	1.18e-07	9	40	3	23345399
Pubmed	De Novo Mutations Affecting the Catalytic Cα Subunit of PP2A, PPP2CA, Cause Syndromic Intellectual Disability Resembling Other PP2A-Related Neurodevelopmental Disorders.	PPP2R5B PPP2R5C PPP2R5D	1.18e-07	9	40	3	30595372
Pubmed	Regulation of Chk2 phosphorylation by interaction with protein phosphatase 2A via its B' regulatory subunit.	PPP2R5B PPP2R5C PPP2R5D	3.08e-07	12	40	3	15380617
Pubmed	Protein phosphatase 2A protects centromeric sister chromatid cohesion during meiosis I.	PPP2R5B PPP2R5C PPP2R5D	3.08e-07	12	40	3	16541024
Pubmed	Bromodomain protein Brd4 regulates human immunodeficiency virus transcription through phosphorylation of CDK9 at threonine 29.	PPP2R5B PPP2R5C PPP2R5D	4.00e-07	13	40	3	18971272
Pubmed	PP2A1 binding, cell transducing and apoptotic properties of Vpr(77-92): a new functional domain of HIV-1 Vpr proteins.	PPP2R5B PPP2R5C PPP2R5D	4.00e-07	13	40	3	21072166
Pubmed	Direct activation of protein phosphatase-2A0 by HIV-1 encoded protein complex NCp7:vpr.	PPP2R5B PPP2R5C PPP2R5D	5.08e-07	14	40	3	9013886
Pubmed	Increasing the ratio of PP2A core enzyme to holoenzyme inhibits Tat-stimulated HIV-1 transcription and virus production.	PPP2R5B PPP2R5C PPP2R5D	5.08e-07	14	40	3	9400615
Pubmed	Dephosphorylation of CDK9 by protein phosphatase 2A and protein phosphatase-1 in Tat-activated HIV-1 transcription.	PPP2R5B PPP2R5C PPP2R5D	5.08e-07	14	40	3	16048649
Pubmed	Regulation of HIV-1 transcription by protein phosphatase 1.	PPP2R5B PPP2R5C PPP2R5D	9.48e-07	17	40	3	17266553
Pubmed	[Action of protein phosphatase-1 on Tat-dependent HIV-1 transcription and its related inhibitors].	PPP2R5B PPP2R5C PPP2R5D	9.48e-07	17	40	3	21351466
Pubmed	Molecular mechanisms involved in HIV-1-Tat mediated inhibition of telomerase activity in human CD4(+) T lymphocytes.	PPP2R5B PPP2R5C PPP2R5D	1.14e-06	18	40	3	23287597
Pubmed	Mechanism and consequences of the duplication of the human C4/P450c21/gene X locus.	TNXA TNXB	1.29e-06	2	40	2	1373808
Pubmed	Sequences promoting the transcription of the human XA gene overlapping P450c21A correctly predict the presence of a novel, adrenal-specific, truncated form of tenascin-X.	TNXA TNXB	1.29e-06	2	40	2	8530023
Pubmed	CYP3A gene expression in human gut epithelium.	CYP3A7 CYP3A5	1.29e-06	2	40	2	7894497
Pubmed	CYP3A genes and the association between prenatal methylmercury exposure and neurodevelopment.	CYP3A7 CYP3A5	1.29e-06	2	40	2	28500872
Pubmed	Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue.	CYP3A7 CYP3A5	1.29e-06	2	40	2	8877031
Pubmed	Shugoshin collaborates with protein phosphatase 2A to protect cohesin.	PPP2R5B PPP2R5C PPP2R5D	1.35e-06	19	40	3	16541025
Pubmed	HIV-1 Vpr induces cell cycle G2 arrest in fission yeast (Schizosaccharomyces pombe) through a pathway involving regulatory and catalytic subunits of PP2A and acting on both Wee1 and Cdc25.	PPP2R5B PPP2R5C PPP2R5D	3.60e-06	26	40	3	11531413
Pubmed	An unequal crossover between the RCCX modules of the human MHC leading to the presence of a CYP21B gene and a tenascin TNXB/TNXA-RP2 recombinant between C4A and C4B genes in a patient with juvenile rheumatoid arthritis.	TNXA TNXB	3.87e-06	3	40	2	10343159
Pubmed	Transcript encoded on the opposite strand of the human steroid 21-hydroxylase/complement component C4 gene locus.	TNXA TNXB	3.87e-06	3	40	2	2475872
Pubmed	The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test.	CYP3A7 CYP3A5	3.87e-06	3	40	2	19801957
Pubmed	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes.	CYP3A7 CYP3A5	3.87e-06	3	40	2	23143891
Pubmed	Development of template systems for ligand interactions of CYP3A5 and CYP3A7 and their distinctions from CYP3A4 template.	CYP3A7 CYP3A5	3.87e-06	3	40	2	33866277
Pubmed	Cytochrome P450 3A gene variation, steroid hormone serum levels and prostate cancer--The Rotterdam Study.	CYP3A7 CYP3A5	3.87e-06	3	40	2	20621111
Pubmed	Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin.	CYP3A7 CYP3A5	3.87e-06	3	40	2	20615193
Pubmed	CYP1A1, CYP3A5 and CYP3A7 polymorphisms and testicular cancer susceptibility.	CYP3A7 CYP3A5	3.87e-06	3	40	2	20345875
Pubmed	Comparison of steroid hormone hydroxylation mediated by cytochrome P450 3A subfamilies.	CYP3A7 CYP3A5	3.87e-06	3	40	2	32001245
Pubmed	CYP3A Polymorphism and Chronic Mercury Intoxication.	CYP3A7 CYP3A5	3.87e-06	3	40	2	32146629
Pubmed	Genetic basis of tobacco smoking: strong association of a specific major histocompatibility complex haplotype on chromosome 6 with smoking behavior.	TNXA TNXB	3.87e-06	3	40	2	15339882
Pubmed	Sequence of the 5'-flanking region of CYP3A5: comparative analysis with CYP3A4 and CYP3A7.	CYP3A7 CYP3A5	3.87e-06	3	40	2	7811260
Pubmed	Differences in CYP3A41G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations.	CYP3A7 CYP3A5	3.87e-06	3	40	2	17582393
Pubmed	Expression of the B56delta subunit of protein phosphatase 2A and Mea1 in mouse spermatogenesis. Identification of a new B56gamma subunit (B56gamma4) specifically expressed in testis.	PPP2R5C PPP2R5D	3.87e-06	3	40	2	15051958
Pubmed	Cytochrome P450 3As gene expression and testosterone 6 beta-hydroxylase activity in human fetal membranes and placenta at full term.	CYP3A7 CYP3A5	3.87e-06	3	40	2	20118548
Pubmed	CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.	CYP3A7 CYP3A5	3.87e-06	3	40	2	34688813
Pubmed	Evaluation of candidate genes for cholinesterase activity in farmworkers exposed to organophosphorus pesticides: association of single nucleotide polymorphisms in BCHE.	PON2 CYP3A7 CYP3A5	5.60e-06	30	40	3	20529763
Pubmed	Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy.	CYP3A7 CYP3A5	7.73e-06	4	40	2	8694864
Pubmed	Control of mitotic exit by PP2A regulation of Cdc25C and Cdk1.	PPP2R5C PPP2R5D	7.73e-06	4	40	2	18056802
Pubmed	1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation.	CYP3A7 CYP3A5	7.73e-06	4	40	2	17885626
Pubmed	Allele and genotype frequencies of CYP3A4, CYP3A5, CYP3A7, and GSTP1 gene polymorphisms among mainland Tibetan, Mongolian, Uyghur, and Han Chinese populations.	CYP3A7 CYP3A5	7.73e-06	4	40	2	34689350
Pubmed	CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.	CYP3A7 CYP3A5	7.73e-06	4	40	2	18978522
Pubmed	Associations Between Cytochrome P450 (CYP) Gene Single-Nucleotide Polymorphisms and Second-to-Fourth Digit Ratio in Chinese University Students.	CYP3A7 CYP11A1	7.73e-06	4	40	2	33723203
Pubmed	An unequal crossover event in RCCX modules of the human MHC resulting in the formation of a TNXB/TNXA hybrid and deletion of the CYP21A.	TNXA TNXB	7.73e-06	4	40	2	12121677
Pubmed	Cytochrome P450 isoforms are differently up-regulated in aflatoxin B₁-exposed human lymphocytes and monocytes.	CYP3A7 CYP3A5	1.29e-05	5	40	2	24168324
Pubmed	The variable subunit associated with protein phosphatase 2A0 defines a novel multimember family of regulatory subunits.	PPP2R5B PPP2R5C	1.29e-05	5	40	2	8694763
Pubmed	Human cytochrome P450 3A7 has a distinct high catalytic activity for the 16alpha-hydroxylation of estrone but not 17beta-estradiol.	CYP3A7 CYP3A5	1.29e-05	5	40	2	14559847
Pubmed	Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene.	CYP3A7 CYP3A5	1.29e-05	5	40	2	11266076
Pubmed	A PP1-PP2A phosphatase relay controls mitotic progression.	PPP2R5C PPP2R5D	1.29e-05	5	40	2	25487150
Pubmed	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites.	CYP3A7 CYP3A5	1.29e-05	5	40	2	11093772
Pubmed	GSTP1 genetic polymorphism is associated with a higher risk of DNA damage in pesticide-exposed fruit growers.	PON2 CYP3A5	1.93e-05	6	40	2	16614106
Pubmed	A PP2A phosphatase high density interaction network identifies a novel striatin-interacting phosphatase and kinase complex linked to the cerebral cavernous malformation 3 (CCM3) protein.	PPP2R5B PPP2R5C PPP2R5D	2.07e-05	46	40	3	18782753
Pubmed	The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons.	CYP3A7 CYP3A5	2.70e-05	7	40	2	11137287
Pubmed	GSK-3beta-dependent phosphorylation of adenomatous polyposis coli gene product can be modulated by beta-catenin and protein phosphatase 2A complexed with Axin.	PPP2R5B PPP2R5C	2.70e-05	7	40	2	10698523
Pubmed	Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk.	CYP3A5 CYP11A1	2.70e-05	7	40	2	17615053
Pubmed	Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients.	CYP3A7 CYP3A5	2.70e-05	7	40	2	19842932
Pubmed	Growth arrest of PPP2R5C and PPP2R5D double knockout mice indicates a genetic interaction and conserved function for these PP2A B subunits.	PPP2R5B PPP2R5D	2.70e-05	7	40	2	35415460
Pubmed	A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.	CYP3A7 CYP3A5	3.60e-05	8	40	2	20147896
Pubmed	Endogenous β-glucocerebrosidase activity in Abca12⁻/⁻epidermis elevates ceramide levels after topical lipid application but does not restore barrier function.	ABCA2 ABCA7	3.60e-05	8	40	2	24293640
Pubmed	Cyclin G2 associates with protein phosphatase 2A catalytic and regulatory B' subunits in active complexes and induces nuclear aberrations and a G1/S phase cell cycle arrest.	PPP2R5B PPP2R5C	3.60e-05	8	40	2	11956189
Pubmed	ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.	CYP3A7 CYP3A5	3.60e-05	8	40	2	19593168
Pubmed	The protein phosphatase 2A regulatory subunits B'beta and B'delta mediate sustained TrkA neurotrophin receptor autophosphorylation and neuronal differentiation.	PPP2R5B PPP2R5D	3.60e-05	8	40	2	19029245
Pubmed	B56-containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX-1 and ERK.	PPP2R5B PPP2R5C	4.62e-05	9	40	2	16456541
Pubmed	Prevalence of common disease-associated variants in Asian Indians.	RET CYP3A5	4.62e-05	9	40	2	18248681
Pubmed	Positive regulation of Raf1-MEK1/2-ERK1/2 signaling by protein serine/threonine phosphatase 2A holoenzymes.	PPP2R5C PPP2R5D	4.62e-05	9	40	2	16239230
Pubmed	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms.	CYP3A7 CYP3A5	5.77e-05	10	40	2	12865317
Pubmed	Association study between single-nucleotide polymorphisms in 199 drug-related genes and commonly measured quantitative traits of 752 healthy Japanese subjects.	CYP3A7 ABCA2 CYP3A5 ABCA7	7.18e-05	193	40	4	19343046
Pubmed	Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants.	CYP3A7 CYP3A5 CYP11A1	7.31e-05	70	40	3	15128046
Pubmed	YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis.	RET TNXB	8.45e-05	12	40	2	10101119
Pubmed	CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.	CYP3A7 CYP3A5	8.45e-05	12	40	2	15319333
Pubmed	Sequence diversity and haplotype structure at the human CYP3A cluster.	CYP3A7 CYP3A5	9.98e-05	13	40	2	16314882
Pubmed	Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.	CYP3A7 CYP3A5	1.73e-04	17	40	2	19424794
Pubmed	Molecular genetics of the human cytochrome P450 monooxygenase superfamily.	CYP3A7 CYP3A5	2.42e-04	20	40	2	9890157
Pubmed	Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.	ABCA2 CYP3A5	2.42e-04	20	40	2	21072184
Pubmed	Intestinal NCoR1, a regulator of epithelial cell maturation, controls neonatal hyperbilirubinemia.	CYP3A5 LPCAT3	4.45e-04	27	40	2	28167773
Pubmed	The tumor suppressor PP2A Abeta regulates the RalA GTPase.	PPP2R5C PPP2R5D	6.26e-04	32	40	2	17540176
Pubmed	Host PDZ-containing proteins targeted by SARS-CoV-2.	FRMPD4 RGS3	7.49e-04	35	40	2	33864728
Pubmed	Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.	CYP3A5 CYP11A1	8.83e-04	38	40	2	20214802
Pubmed	PTEN identified as important risk factor of chronic obstructive pulmonary disease.	CYP3A7 RET OGG1 ABCA7	8.86e-04	374	40	4	19625176
Pubmed	Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway.	CYP3A7 RET OGG1 ABCA7	9.49e-04	381	40	4	18676680
Pubmed	Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China.	CYP3A7 RET OGG1 ABCA7	9.58e-04	382	40	4	19170196
Pubmed	Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women.	CYP3A7 FUCA1 CYP3A5	9.93e-04	170	40	3	19064572
Pubmed	Population based allele frequencies of disease associated polymorphisms in the Personalized Medicine Research Project.	PON2 RET	1.13e-03	43	40	2	20565774
Interaction	CCNG2 interactions	PPP2R5B PPP2R5C PPP2R5D	4.13e-06	17	38	3	int:CCNG2
Interaction	FAM43A interactions	PPP2R5B PPP2R5C PPP2R5D	4.23e-05	36	38	3	int:FAM43A
Interaction	CYP3A7 interactions	CYP3A7 CYP3A5	5.17e-05	6	38	2	int:CYP3A7
Interaction	WNT3A interactions	PPP2R5B PPP2R5C PPP2R5D	1.07e-04	49	38	3	int:WNT3A
Interaction	PPFIA3 interactions	PPP2R5B PPP2R5C PPP2R5D	1.69e-04	57	38	3	int:PPFIA3
GeneFamily	WD repeat domain containing\|Protein phosphatase 2 regulatory subunits	PPP2R5B PPP2R5C PPP2R5D	1.85e-06	15	30	3	696
GeneFamily	Cytochrome P450 family 3	CYP3A7 CYP3A5	7.41e-05	8	30	2	1002
GeneFamily	ATP binding cassette subfamily A	ABCA2 ABCA7	2.39e-04	14	30	2	805
Coexpression	GSE19374_UNINF_VS_LISTERIA_INFECTED_MACROPHAGE_DN	CATSPERB PPP2R5B LINC01587 PARM1 CFHR4	1.24e-05	198	40	5	M7265
Drug	diphenylcyclopropane	RET CYP3A5	2.86e-06	2	39	2	CID000070824
Drug	AC1L4PY8	CYP3A5 CYP11A1	8.57e-06	3	39	2	CID000161717
Drug	AC1L1E9D	OGG1 CYP3A5	8.57e-06	3	39	2	CID000027932
Drug	SU 8000	CYP3A5 CYP11A1	1.71e-05	4	39	2	CID000159647
Drug	22-ABC	CYP3A5 CYP11A1	1.71e-05	4	39	2	CID000127605
Drug	verapamil	CYP3A7 ABCA2 LINC01587 CYP3A5 ABCA7 RYR2 CFHR4	1.74e-05	490	39	7	CID000002520
Drug	tienilic acid	CYP3A7 LINC01587 CYP3A5 CYP11A1	1.92e-05	93	39	4	CID000038409
Drug	Pentolinium bitartrate [52-62-0]; Up 200; 7.4uM; MCF7; HT_HG-U133A	ADAMTS5 OGG1 CYP3A5 RYR2 GNPTAB	2.09e-05	197	39	5	2305_UP
Drug	2-propylpentanoic acid; Up 200; 50uM; PC3; HT_HG-U133A	ABCA2 RET CWH43 LINC01587 RYR2	2.14e-05	198	39	5	4446_UP
Drug	chlorpyrifos	PON2 CYP3A7 WAS CYP3A5	2.66e-05	101	39	4	CID000002730
Drug	21-deoxycortisol	CYP3A5 TNXB CYP11A1	4.07e-05	39	39	3	CID000092827
Drug	kaurenol	CYP3A5 CYP11A1	4.27e-05	6	39	2	CID000443465
Drug	APAP-CYS	CYP3A5 AASS	4.27e-05	6	39	2	CID000083967
Drug	Alfentanil	CYP3A7 CYP3A5	4.27e-05	6	39	2	ctd:D015760
Drug	hexabromocyclododecane	CYP3A7 OGG1 ABCA7 CYP11A1 RYR2	4.29e-05	229	39	5	ctd:C089796
Drug	tridigitoxoside	CYP3A5 ABCA7 CYP11A1	4.39e-05	40	39	3	CID000003061
Drug	o-quinone	CYP3A7 OGG1 CYP3A5	4.74e-05	41	39	3	CID000011421
Drug	17-hydroxyprogesterone	PON2 CYP3A5 TNXB CYP11A1	5.76e-05	123	39	4	CID000006238
Drug	MeSO2-DDE	CYP3A5 CYP11A1	5.97e-05	7	39	2	CID000119115
Drug	Oxy-16	CYP3A5 CYP11A1	5.97e-05	7	39	2	CID005118785
Drug	4-nitro-2,4-diazabutanal	CYP3A5 TNXB	7.95e-05	8	39	2	CID009543266
Drug	fentichlor	CYP3A7 CYP3A5 AASS	8.11e-05	49	39	3	CID000007329
Drug	epicholesterol	PON2 ABCA2 LINC01587 CYP3A5 ABCA7 CYP11A1 CFHR4	9.07e-05	636	39	7	CID000000304
Drug	phenylthioacetate	PON2 CYP3A5	1.02e-04	9	39	2	CID000007631
Drug	S 840	CYP3A7 CYP3A5	1.02e-04	9	39	2	CID000096338
Drug	dicyclanil	OGG1 CYP3A5	1.02e-04	9	39	2	CID003081364
Drug	sodium rosmarinate	OGG1 CYP3A5 TNXB	1.03e-04	53	39	3	CID000005099
Drug	ABAP	PON2 ABCA2 ABCA7	1.03e-04	53	39	3	CID000001969
Drug	clotrimazole	CYP3A7 ABCA2 CYP3A5 CYP11A1	1.03e-04	143	39	4	CID000002812
Drug	triazolam	CYP3A7 CYP3A5 AASS	1.08e-04	54	39	3	CID000005556
Drug	4-hydroxymidazolam	CYP3A7 CYP3A5	1.28e-04	10	39	2	CID000124449
Drug	PCB 66	CYP3A5 RYR2	1.56e-04	11	39	2	CID000036185
Drug	rogletimide	CYP3A5 CYP11A1	1.56e-04	11	39	2	CID000056487
Drug	Ticalopride	CYP3A7 CYP3A5	1.56e-04	11	39	2	CID000216236
Drug	Troleandomycin	CYP3A7 CYP3A5	1.56e-04	11	39	2	ctd:D014217
Drug	lidocaine	RET LINC01587 CYP3A5 RYR2	1.59e-04	160	39	4	CID000003676
Drug	paraoxon	PON2 CYP3A7 CYP3A5 CYP11A1	1.75e-04	164	39	4	CID000009395
Drug	11-deoxycortisol	CYP3A5 TNXB CYP11A1	1.80e-04	64	39	3	CID000009050
Drug	7 cholesterol	CYP3A5 CYP11A1 GNPTAB	1.80e-04	64	39	3	CID000000420
Drug	clofibrate	CYP3A7 LINC01587 CYP3A5 CYP11A1 CFHR4	1.81e-04	311	39	5	CID000002796
Drug	flumecinol	PON2 CYP3A5	1.87e-04	12	39	2	CID000041870
Drug	isocytisoside	CYP3A5 AASS	1.87e-04	12	39	2	CID000160749
Drug	NSC126729	OGG1 CYP3A5	1.87e-04	12	39	2	CID000030816
Drug	halothane	CYP3A7 LINC01587 CYP3A5 CYP11A1 RYR2	1.89e-04	314	39	5	CID000003562
Drug	felodipine	CYP3A7 CYP3A5 CYP11A1 RYR2	1.97e-04	169	39	4	CID000003333
Drug	propoxyphene	CYP3A7 CYP3A5 CYP11A1	2.06e-04	67	39	3	CID000010100
Drug	p-aminophenol	PON2 CYP3A5 AASS	2.16e-04	68	39	3	CID000000403
Drug	creosol	RET CYP3A5	2.20e-04	13	39	2	CID000007144
Drug	fluazifop-butyl	PON2 CYP3A5	2.20e-04	13	39	2	CID000050897
Drug	carteolol	CYP3A7 CYP3A5 CYP11A1	2.55e-04	72	39	3	CID000002583
Drug	propionanilide	CYP3A7 CYP3A5	2.57e-04	14	39	2	CID000012107
Drug	NSC118131	CYP3A5 CYP11A1	2.57e-04	14	39	2	CID000011300
Drug	7-BFC	CYP3A7 CYP3A5	2.57e-04	14	39	2	CID000848780
Drug	Meclizine	RET CYP3A5	2.57e-04	14	39	2	ctd:D008468
Drug	Seneciphynine	RET CYP3A5	2.57e-04	14	39	2	CID000010196
Drug	eserine hemisulfate	PON2 RET CYP3A5	2.77e-04	74	39	3	CID000004811
Drug	AC1L1E5T	LINC01587 CYP3A5 AASS	2.77e-04	74	39	3	CID000002653
Drug	senecionine	CYP3A7 CYP3A5 CYP11A1	2.77e-04	74	39	3	ctd:C009237
Drug	Epi Lovastatin	PON2 CYP3A7 CYP3A5 CYP11A1 CFHR4	2.77e-04	341	39	5	CID000003962
Drug	CAS 93957-55-2	PON2 CYP3A7 CYP3A5 CFHR4	2.89e-04	187	39	4	CID000003403
Drug	tri-(2-chloroisopropyl)phosphate	CYP3A7 CYP11A1	2.96e-04	15	39	2	ctd:C072782
Drug	6-oxohexanoate	OGG1 AASS	2.96e-04	15	39	2	CID000440918
Drug	fludrocortisone	CYP3A5 TNXB CYP11A1	3.00e-04	76	39	3	CID000031378
Drug	11-cis-retinal	ABCA2 RET CYP3A5 CFHR4	3.01e-04	189	39	4	CID000001070
Drug	3-isoreserpine	ABCA2 LINC01587 CYP3A5 ABCA7	3.08e-04	190	39	4	CID000005052
Drug	Myricetin [529-44-2]; Down 200; 12.6uM; HL60; HT_HG-U133A	FUCA1 RET OGG1 ATG2B	3.08e-04	190	39	4	1334_DN
Drug	NSC759576	CYP3A7 LINC01587 CYP3A5 RYR2	3.14e-04	191	39	4	CID000003075
Drug	alprazolam	CYP3A7 CYP3A5 AASS CYP11A1	3.26e-04	193	39	4	CID000002118
Drug	Rapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A	ZFYVE26 OGG1 RGS3 LPCAT3	3.26e-04	193	39	4	6981_DN
Drug	Dirithromycin [62013-04-1]; Down 200; 4.8uM; MCF7; HT_HG-U133A	ABCA2 WAS ABCA7 GNPTAB	3.33e-04	194	39	4	2863_DN
Drug	Clofilium tosylate [92953-10-1]; Down 200; 7.8uM; PC3; HT_HG-U133A	ABCA2 PPP2R5B ABCA7 AASS	3.33e-04	194	39	4	4492_DN
Drug	glutethimide	CYP3A5 CYP11A1	3.38e-04	16	39	2	CID000003487
Drug	aa cysteine	CYP3A5 AASS	3.38e-04	16	39	2	CID000083997
Drug	1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane	CYP3A5 CYP11A1	3.38e-04	16	39	2	ctd:C495657
Drug	IMOL S-140	CYP3A7 CYP11A1	3.38e-04	16	39	2	ctd:C011582
Drug	Thalidomide [50-35-1]; Up 200; 15.4uM; PC3; HT_HG-U133A	GPR6 ADAMTS5 ABCA7 CYP11A1	3.39e-04	195	39	4	7288_UP
Drug	15d-PGJ2; Down 200; 10uM; MCF7; HT_HG-U133A	RET WAS OGG1 RGS3	3.39e-04	195	39	4	5591_DN
Drug	Protoveratrine A [143-57-7]; Up 200; 5uM; MCF7; HT_HG-U133A	PPP2R5B WAS CYP3A5 RYR2	3.46e-04	196	39	4	2800_UP
Drug	trimipramine	CYP3A7 CYP3A5 CYP11A1	3.48e-04	80	39	3	CID000005584
Drug	hydroxyl radicals	PON2 CYP3A7 FUCA1 PPP2R5B PPP2R5D USP9Y CYP3A5 AASS CYP11A1	3.52e-04	1341	39	9	CID000000961
Drug	alpha-estradiol; Up 200; 0.01uM; MCF7; HT_HG-U133A	ABCA2 PPP2R5B RET WAS	3.53e-04	197	39	4	1635_UP
Drug	AC1Q6O8T	PON2 CYP3A7 CYP3A5 CYP11A1	3.53e-04	197	39	4	CID000002193
Drug	Cefoxitin sodium salt [33564-30-6]; Up 200; 8.8uM; MCF7; HT_HG-U133A	ABCA2 PPP2R5D LINC01587 LPCAT3	3.53e-04	197	39	4	6796_UP
Drug	Propidium iodide [25535-16-4]; Down 200; 6uM; PC3; HT_HG-U133A	ABCA7 AASS RYR2 PARM1	3.53e-04	197	39	4	5803_DN
Drug	Acyclovir [59277-89-3]; Up 200; 17.8uM; MCF7; HT_HG-U133A	GPR6 ABCA2 PPP2R5B PPP2R5C	3.53e-04	197	39	4	1543_UP
Drug	6-Furfurylaminopurine [525-79-1]; Down 200; 18.6uM; PC3; HT_HG-U133A	ABCA2 CWH43 ABCA7 PARM1	3.53e-04	197	39	4	4477_DN
Drug	Atractyloside potassium salt [102130-43-8]; Down 200; 5uM; MCF7; HT_HG-U133A	PPP2R5B AASS LPCAT3 RYR2	3.53e-04	197	39	4	4717_DN
Drug	dibutyryl cyclic 3',5'-AMP	LINC01587 CYP3A5 ABCA7 CYP11A1 NLK CFHR4	3.56e-04	561	39	6	CID000002460
Drug	PF-00562151-00 [351320-12-2]; Up 200; 10uM; PC3; HT_HG-U133A	ABCA2 LPCAT3 PARM1 ATG2B	3.60e-04	198	39	4	6907_UP
Drug	tolbutamide	CYP3A7 LINC01587 CYP3A5 CYP11A1	3.60e-04	198	39	4	CID000005505
Drug	Cyanocobalamin [68-19-9]; Up 200; 3uM; MCF7; HT_HG-U133A	PPP2R5B WAS CYP3A5 RGS3	3.60e-04	198	39	4	4395_UP
Drug	Alverine citrate salt [5560-59-8]; Up 200; 8.4uM; PC3; HT_HG-U133A	PPP2R5B ABCA7 RYR2 PARM1	3.60e-04	198	39	4	6345_UP
Drug	Dimaprit dihydrochloride [23256-33-9]; Up 200; 17uM; MCF7; HT_HG-U133A	ADAMTS5 USP9Y RGS3 GNPTAB	3.60e-04	198	39	4	6520_UP
Drug	Tropine [120-29-6]; Down 200; 28.4uM; PC3; HT_HG-U133A	CWH43 RYR2 GNPTAB PARM1	3.60e-04	198	39	4	5790_DN
Drug	Methacholine chloride [62-51-1]; Down 200; 20.4uM; PC3; HT_HG-U133A	PPP2R5B WAS LPCAT3 RYR2	3.67e-04	199	39	4	5773_DN
Drug	Molsidomine [25717-80-0]; Up 200; 16.6uM; MCF7; HT_HG-U133A	ABCA2 LINC01587 LPCAT3 GNPTAB	3.67e-04	199	39	4	5426_UP
Drug	Nitrofurantoin [67-20-9]; Up 200; 16.8uM; PC3; HT_HG-U133A	GPR6 ADAMTS5 WAS CYP3A5	3.67e-04	199	39	4	3674_UP
Drug	Tracazolate hydrochloride [41094-88-6]; Down 200; 11.8uM; MCF7; HT_HG-U133A	ABCA2 OGG1 RGS3 RYR2	3.67e-04	199	39	4	7339_DN
Drug	cyclosporine A; Down 200; 1uM; MCF7; HG-U133A	PPP2R5B PPP2R5C ADAMTS5 RGS3	3.74e-04	200	39	4	261_DN
Drug	Felbinac [5728-52-9]; Up 200; 18.8uM; MCF7; HT_HG-U133A	ABCA2 LINC01587 OGG1 RYR2	3.74e-04	200	39	4	5700_UP
Disease	tacrolimus measurement	CYP3A7 CYP3A5	1.02e-05	4	39	2	EFO_0008458
Disease	metabolonic lactone sulfate measurement	CYP3A7 CYP3A5	2.87e-04	19	39	2	EFO_0800659
Disease	Lymphoma	WAS OGG1	1.29e-03	40	39	2	C0024299

Protein segments in the cluster

Peptide	Gene	Start	Entry
ILHRVYGKFLGLRAY	PPP2R5B	216	Q15173
YYDHLGFLHKLTLGR	CATSPERB	496	Q9H7T0
LLYLYGTRTHGLFKR	CYP3A5	21	P20815
RLYGRGLQHYLLTLA	ADAMTS5	281	Q9UNA0
SAHTLLRGTLRYKGY	AASS	716	Q9UDR5
ILHRIYGKFLGLRAY	PPP2R5D	261	Q14738
LHRIYGKFLGLRAYI	PPP2R5C	186	Q13362
NFYLLLSIGHYGRKS	LINC01587	36	Q99440
SYRHGLLGVDKLFSY	ATG2B	1856	Q96BY7
RRHLGSGYYLTLVKA	ABCA7	1026	Q8IZY2
YYLLGEHLGRTKHLK	RGS3	256	P49796
YYSRRTLLGVHLLLA	GPR6	176	P46095
LLGRKLQHYTDSYLG	GNPTAB	876	Q3T906
ALRKRNIRYGLYHSL	FUCA1	171	P04066
LKRLSLGLFYLVGYT	LPCAT3	231	Q6P1A2
YQILRGLKYLHSAGI	NLK	246	Q9UBE8
LRKLGLGYRARYVSA	OGG1	196	O15527
ARLRKYDIGGKYSHL	NUDT7	21	P0C024
VAAYLKIRHSSYGRL	PARM1	276	Q6UWI2
YDGKLLIGTLYHRAL	PON2	336	Q15165
KVHYLKFLSDLRLYG	FRMPD4	406	Q14CM0
FLLGRYLARHKGTYL	CADM2	386	Q8N3J6
YLLFTSDRFRLHRYG	ABCA2	1681	Q9BZC7
LNIYFKSRGGSYHRL	CERS1	221	P27544
HDYRGILYRLLGDSK	CYP11A1	296	P05108
HGGLYYKSLRRLYFP	CFHR4	31	Q92496
DIYVTGGHLFYRLLR	KLHDC7B	451	Q96G42
GGHLFYRLLRYSPVK	KLHDC7B	456	Q96G42
LLYLYGTRTHGLFKK	CYP3A7	21	P24462
RTLLYGHAILLRHSY	RYR2	111	Q92736
MYRGLIRLGYARISH	CWH43	616	Q9H720
YRLASLYLHYLGLLR	IQCA1L	41	A6NCM1
REKKLYFGYSLLGAH	PXYLP1	336	Q8TE99
KRSHQRLFPGLYLGY	ANKFN1	601	Q8N957
LDAGRKYRFLLYGLL	TNXB	1731	P22105
SRKYRFLLYGLSGRK	TNXB	3416	P22105
KSYFIRLYGLQAGRL	WAS	81	P42768
GKYSGDYFTLLRHLL	USP9Y	1371	O00507
TPYRFLLYGLHEGKR	TNXA	106	Q16473
FRLGQHLYGTYRTRL	RET	66	P07949
KASRGLLSLYGHTYA	ZFYVE26	266	Q68DK2
FGYLLKGRQLLHTTY	TMEM145	191	Q8NBT3